
Assessment of Formulation Use

Kevin Bradley, University of Missouri




Estimates of the Dicamba Formulations Used on Xtend Soybean and Cotton in 2017




^{*}estimates obtained from 22 university scientists across 19 states

Percent of Total Off-target Injury Attributed to the Use of Non-labeled Dicamba Formulations in 2017



*estimates obtained from 22 university scientists across 19 states

An Example from One Missouri Ag Retailer/Co-op



Final Thoughts

Certain states have already taken efforts to make stand-alone dicamba products restricted use. Will this have to occur on a larger scale in the future?

How much of a data gap do we really have? Seed suppliers and registrants have sales information pertaining to Xtend seed and Engenia, Xtendimax, and FeXapan that will be (and would have been) very helpful in informing the situation.

Current university data indicates no difference between the DGA and the new formulations anyway!

